Jurgi Camblong Sells 22,486 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 22,486 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $5.25, for a total value of $118,051.50. Following the completion of the sale, the chairman owned 3,558,807 shares of the company’s stock, valued at $18,683,736.75. This trade represents a 0.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total value of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total value of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.24, for a total value of $44,540.00.
• On Monday, April 20th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.21, for a total value of $23,372.06.
• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.00, for a total value of $87,365.00.
• On Tuesday, April 14th, Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total value of $213,919.84.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total transaction of $20,939.24.
• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.72, for a total transaction of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total transaction of $13,552.00.

SOPHiA GENETICS Trading Up 1.9%

Shares of SOPHiA GENETICS stock traded up $0.10 during mid-day trading on Tuesday, hitting $5.44. The stock had a trading volume of 284,463 shares, compared to its average volume of 187,273. The firm has a 50-day moving average of $5.12 and a two-hundred day moving average of $4.96. The firm has a market cap of $456.36 million, a P/E ratio of -10.46 and a beta of 0.96. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. SOPHiA GENETICS SA has a 12-month low of $2.92 and a 12-month high of $6.30.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The firm had revenue of $21.69 million for the quarter, compared to analysts’ expectations of $20.40 million.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. BTIG Research reissued a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, SOPHiA GENETICS currently has an average rating of “Hold” and an average price target of $7.50.

Hedge Funds Weigh In On SOPHiA GENETICS

Hedge funds have recently made changes to their positions in the stock. 1492 Capital Management LLC purchased a new stake in SOPHiA GENETICS in the fourth quarter valued at approximately $973,000. Royce & Associates LP purchased a new position in shares of SOPHiA GENETICS during the fourth quarter worth $2,009,000. Hodges Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS in the first quarter valued at $2,157,000. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS in the first quarter valued at $50,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at $54,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.